Glomalin-related soil protein (GRSP) is known as an important microbial by-product which is crucial for preserving or accumulating soil organic carbon (SOC). However, the underlying mechanisms are not well understood. In this study, we investigated the chemical structures of GRSP and its relationship with SOC using 13C nuclear magnetic resonance (NMR) in three tropical forests. The three forests, including a planted forest (PF), a secondary forest (MF) and a primary forest (BF), were selected to represent the natural successional process after disturbance in southern China. Results showed that the average concentrations of GRSP were (3.94 ± 1.09) mg cm−3 and accounting for (3.38 ± 1.15)% of the SOC in the top 10 cm soil. NMR analysis indicated rich aromatic C (~30%) and carboxyl C (~40%) in GRSP, and abundant alkyl C (~30%) and O-alkyl C (~50%) in SOC. The recalcitrance indexes (RI), as defined as the ratio of sum of alkyl C and aromatic C over sum of O-alkyl C and carboxyl C, was (98.6 ± 18.9)%, (145.5 ± 10.9)% and (20.7 ± 0.3)% in GRSP higher than that in SOC in the PF, MF and BF, respectively. This study demonstrated that the stubborn structure of GRSP probably regulate the resistance of SOC sequestration in tropical forests, especially in the planted and secondary forests.
Context.— The updated American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer requires pathologists to re-evaluate HER2 status. Objective.— To define HER2 status of breast cancer using immunohistochemistry and fluorescence in situ hybridization. Design.— Diagnostic reports of invasive breast cancers made between 2014 and 2018 with HER2 immunohistochemistry and fluorescence in situ hybridization results were retrieved. HER2 status was re-defined using the updated recommendations. Results.— Of 2514 tumors, 89.7% (2254 of 2514) suggested for fluorescence in situ hybridization assay were HER2 immunohistochemistry 2+. Approximately 8.9% (225 of 2514) and 1.4% (35 of 2514) of tumors were of immunohistochemistry 0/1+ and 3+, respectively. Based on the average HER2 copy number and HER2:CEP17 ratio, tumors were assigned into 5 groups, including 13.1% (330 of 2514) group 1 tumors, 2.1% (52 of 2514) group 2 tumors, 1.1% (27 of 2514) group 3 tumors, 7.0% (175 of 2514) group 4 tumors, and 76.8% (1930 of 2514) group 5 tumors. In combination with immunohistochemistry, all tumors in group 2 and group 4 changed HER2 status, from positive and equivocal into negative, respectively, while group 3 tumors remained positive. Comparative analyses of clinicopathologic features of tumors in different groups revealed that group 2 and 4 tumors displayed worse clinicopathologic features than those of group 5, while group 3 tumors shared similar clinicopathologic features to those of group 1. Conclusions.— Following the updated guideline, HER2 status is clearly designated. Significant differences regarding clinical features were observed between tumors in different groups but they share the same HER2 status, suggesting further validation of the accuracy of this diagnostic approach is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.